The Coalition for Global Hepatitis Elimination, in partnership with Clinical Liver Disease (CLD), a journal of the American Association for the Study of Liver Disease, is launching a new series to highlight efforts advancing hepatitis B and C elimination globally. This series will provide an opportunity to publish timely reports on real world experience in planning, designing, implementing, and evaluating hepatitis elimination programs or projects. With the series greater emphasis on the “how-to” of hepatitis elimination, short editorial-style articles and reports in this series will more readily share lessons learned and new data. We hope this will help the community of practice capture and apply lessons to accelerate progress towards elimination.
More about the journal: Clinical Liver Disease (CLD) is a digital educational resource published on behalf of the American Association for the Study of Liver Diseases (AASLD). Each issue delivers between eight and fifteen short articles (approximately 800-1000 words, 10 references, and 4-5 graphics), as well as relevant links to other AASLD online educational material. CLD articles are accompanied by podcasts, video interviews, and/or slide sets that help emphasize the key teaching points for a clinical audience, and readers can earn Continuing Medical Education (CME) credits for reading, watching, and listening to the content.
Objective of this series: Provide a forum for clinicians, civil society, health authorities, and others to share experiences in hepatitis elimination efforts, including program planning process, program design, implementation strategies, challenges and outcomes
General guidance for submission
These reports can feature descriptions of:
- The elimination planning process, including creating partnerships, analysis of strategic information, mobilization of civil and political support, and budgeting;
- The elimination program design, including objectives, target populations and settings, inclusion of key populations, and financing plan;
- Strategies and outcomes associated with implementation of community or clinic-based interventions to prevent, detect, care for, and treat people living with viral hepatitis, and increase community awareness and/or change policy;
- Changes in prevention and treatment priorities as revealed by program outcomes, public health surveillance or other strategic health information;
- Concise syntheses of systematic reviews to inform program planning and design;
Reports should preferably reflect recent efforts (i.e. within the last 2 years).
Each submission should be 800–1,200 words in length and may contain up to 10 references and 5 graphics.
Find additional author guidance on manuscript organization, copyright, conflict of interests, and patient privacy in the document to the right.
Submissions are accepted on a rolling basis.
General inquiries: If you would like to discuss your article idea, please send your inquiry to our editorial team here.
Editorial assistance: Reports must be submitted in English. Editorial assistance is available for authors whom English is a second language or with little or no experience in report writing. To receive this assistance, fill out this form and select "Editorial support." Language and writing proficiency will not affect article selection.
Submissions for publication: To submit for publication, please fill out this form, as well.
If accepted for publication, the Coalition will first work with the authors on editorial concerns, if needed, and then transmit the articles to Clinical Liver Disease.
There is no publication fee for Clinical Liver Disease. All accepted submissions will be available online at https://aasldpubs.onlinelibrary.wiley.com/journal/20462484 and www.globalhep.org.
Audio/Visual Emphasis: After acceptance of your written article, the Editorial Board will determine the audio/visual format that will best illustrate the educational message. At that time, AASLD staff will attempt to schedule an interview to be taped, podcast to be recorded, etc, that is convenient for you and maintains our production schedule.